A Phase 3 interventional study of Voclosporin and Placebo Oral Capsule in Lupus Nephritis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-14.
Sponsored by Aurinia Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.
Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 17th largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2019, is one of 16 in phase 3, and was the 43rd registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
iCell Gene Therapeutics · Sites in United States
Ages 16–70
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 47 · Phase 3 17 · Phase 4 7
First in 1994; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 216 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 100 interventional studies, 265 across the 14 observational. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 114 have an industry lead sponsor. The 10 most frequent:
Aurinia Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Aurinia Pharmaceuticals Inc. has 8 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
11 of the studies in Lupus Nephritis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06518668Hospital for Special Surgery, New YorkA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06217107Morehouse School of MedicineWellness & Workforce Solution for Lupus/Lupus Nephritis | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 114 studies in Lupus Nephritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN).
The aim of the Phase 3 continuation study (AURORA 2) is to assess the long-term safety and tolerability of voclosporin, added to the standard of care treatment in LN, for an additional 24 months, following a treatment period of 52 weeks in the AURORA 1 study (AUR-VCS-2016-01). All subjects will continue to receive background therapy of mycophenolate mofetil (MMF) and/or oral corticosteroids starting at the same dose as at the end of the AURORA 1 study. Subjects with LN, who have completed 52 weeks of treatment with study drug in the AURORA 1 study, will be eligible to enter the study. The long-term safety and tolerability of the drug combination will be assessed from its safety profile while demonstrating the continued ability to achieve and maintain long-term renal response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Voclosporin
Drug: Voclosporin
Placebo
Drug: Placebo Oral Capsule
Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)
Also known as: ISA247
Voclosporin placebo, oral, 3 capsules twice daily (BID)
Adverse Events (AE) Profile and Routine Biochemical and Hematological Assessments.
Number (and percent) of adverse events experienced during the AURORA 2 treatment period. To assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with LN.
Time frame: Month 12 (AURORA 2 baseline) to Month 36
Number (and Percent) of Subjects in Renal Response
Proportion of subjects in renal response defined as: * urine protein creatinine ratio (UPCR) of ≤0.5 mg/mg * estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 or no confirmed decrease from baseline in eGFR of \>20% * Received no rescue medication for LN * Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during the 8 weeks prior to the renal response assessment.
Time frame: Months 12 (AURORA 2 Baseline), 18, 24, 30 and 36
Number (and Percent) of Subjects in Partial Renal Response
Partial renal response defined as a 50% reduction from baseline in urine protein creatinine ratio (UPCR).
Time frame: Months 12 (AURORA 2 baseline), 18, 24, 30 and 36
Renal Flare as Adjudicated by the Clinical Endpoints Committee (CEC).
A patient could experience a flare from the point they achieved a response (or recovery). Renal flares were judged according to the following criteria: * A reproducible increase to UPCR \>1 mg/mg from a post-response baseline of \<0.2 mg/mg or * an increase to UPCR \>2 mg/mg from a post-response baseline between 0.2 to 1.0 mg/mg or * a doubling of UPCR for baseline values of UPCR \>1 mg/mg
Time frame: Month 12 (AURORA 2 baseline) to Month 36
Change From AURORA 1 Baseline (i.e., Month 0) in Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)
Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Assessment of Systemic Lupus Erythematosus (SLE) Disease Activity within the last 10 days. It scores 24 disease descriptors across 9 organ systems which are summed to a minimum of \<2 (considered indicative of no activity) and maximum of 105 points. Scores are weighted and a score of 6 is considered clinically significant. Higher scores indicate worse disease activity.
Time frame: Months 18, 24 and 36
Change From AURORA 1 Baseline (i.e., Month 0) in Urine Protein to Creatinine Ratio (UPCR)
Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Reductions in UPCR are indicative of better renal outcomes.
Time frame: Months 12 (AURORA 2 baseline), 18, 24, 30 and 36
Change From AURORA 1 Baseline (i.e., Month 0) in Estimated Glomerular Filtration Rate (eGFR)
Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. This endpoint incorporated Corrected eGFR values with a ceiling set to 90 mL/min/1.73 m\^2 Increases in eGFR levels are indicative of better renal outcomes.
Time frame: Months 12 (AURORA 2 baseline), 18, 24, 30 and 36
Change From AURORA 1 Baseline (i.e., Month 0) in Urine Protein
Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Reductions in Urine Protein levels are indicative of better renal outcomes.
Time frame: Months 12 (AURORA 2 baseline), 18, 24, 30 and 36
Change From AURORA 1 Baseline (i.e., Month 0) in Serum Creatinine (SCr)
Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Decreases in SCr levels can be indicative of better renal outcomes.
Time frame: Months 12 (AURORA 2 baseline), 18, 24, 30 and 36
| Milestone | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Started | 116 | 100 |
| Completed | 101 | 85 |
| Not completed | 15 | 15 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Pregnancy | 3 | 1 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Death | 0 | 3 |
Number (and percent) of adverse events experienced during the AURORA 2 treatment period. To assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with LN.
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 100 | 80 |
| Treatment-related TEAE | 28 | 21 |
| Serious TEAE | 21 | 23 |
| TEAE leading to study drug discontinuation | 11 | 17 |
| TEAE leading to death | 0 | 3 |
| Treatment-related TEAE leading to death | 0 | 0 |
| Disease-related TEAE | 50 | 34 |
| Disease-related serious TEAE | 7 | 11 |
Proportion of subjects in renal response defined as: * urine protein creatinine ratio (UPCR) of ≤0.5 mg/mg * estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 or no confirmed decrease from baseline in eGFR of \>20% * Received no rescue medication for LN * Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during the 8 weeks prior to the renal response assessment.
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Renal Response - Month 12 | 61 | 34 |
| Renal Response - Month 18 | 74 | 46 |
| Renal Response - Month 24 | 65 | 43 |
| Renal Response - Month 30 | 69 | 42 |
| Renal Response - Month 36 | 59 | 39 |
Partial renal response defined as a 50% reduction from baseline in urine protein creatinine ratio (UPCR).
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Partial Renal Response - Month 12 | 104 | 70 |
| Partial Renal Response - Month 18 | 96 | 68 |
| Partial Renal Response - Month 24 | 90 | 58 |
| Partial Renal Response - Month 30 | 85 | 61 |
| Partial Renal Response - Month 36 | 86 | 69 |
A patient could experience a flare from the point they achieved a response (or recovery). Renal flares were judged according to the following criteria: * A reproducible increase to UPCR \>1 mg/mg from a post-response baseline of \<0.2 mg/mg or * an increase to UPCR \>2 mg/mg from a post-response baseline between 0.2 to 1.0 mg/mg or * a doubling of UPCR for baseline values of UPCR \>1 mg/mg
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Subjects without adequate response or with flares | 39 | 46 |
| Subjects with adequate response and wothout flares | 77 | 54 |
Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Assessment of Systemic Lupus Erythematosus (SLE) Disease Activity within the last 10 days. It scores 24 disease descriptors across 9 organ systems which are summed to a minimum of \<2 (considered indicative of no activity) and maximum of 105 points. Scores are weighted and a score of 6 is considered clinically significant. Higher scores indicate worse disease activity.
| Scores on a scale | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Month 18 | -6.4 (-7.4 to -5.4) | -5.6 (-6.6 to -4.5) |
| Month 24 | -6.8 (-7.7 to -5.9) | -6.1 (-7.0 to -5.1) |
| Month 36 | -6.8 (-7.7 to -5.9) | -6.1 (-7.1 to -5.2) |
Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Reductions in UPCR are indicative of better renal outcomes.
| mg/mg | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Month 12 (AURORA 2 baseline) | -3.17 ± 0.164 | -2.52 ± 0.175 |
| Month 18 | -3.05 ± 0.216 | -2.42 ± 0.232 |
| Month 24 | -3.18 ± 0.188 | -2.41 ± 0.202 |
| Month 30 | -3.12 ± 0.219 | -2.21 ± 0.235 |
| Month 36 | -3.00 ± 0.222 | -2.52 ± 0.236 |
Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. This endpoint incorporated Corrected eGFR values with a ceiling set to 90 mL/min/1.73 m\^2 Increases in eGFR levels are indicative of better renal outcomes.
| mL/min/1.73 m^2 | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Month 12 (AURORA 2 baseline) | 1.8 ± 1.08 | 4.4 ± 1.15 |
| Month 18 | -0.2 ± 1.31 | 1.6 ± 1.40 |
| Month 24 | -1.3 ± 1.48 | 0.9 ± 1.60 |
| Month 30 | 0.2 ± 1.56 | -0.8 ± 1.67 |
| Month 36 | -0.2 ± 1.69 | -2.0 ± 1.81 |
Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Reductions in Urine Protein levels are indicative of better renal outcomes.
| mg/dL | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Month 12 (AURORA 2 baseline) | -302.4 ± 16.91 | -234.6 ± 18.05 |
| Month 18 | -297.8 ± 23.41 | -210.1 ± 25.15 |
| Month 24 | -295.8 ± 17.10 | -248.8 ± 18.51 |
| Month 30 | -304.7 ± 19.23 | -231.6 ± 20.67 |
| Month 36 | -280.7 ± 22.66 | -261.7 ± 24.01 |
Participants analyzed included all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for those subjects that continued in AURORA 2. Decreases in SCr levels can be indicative of better renal outcomes.
| mg/dL | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Month 12 (AURORA 2 baseline) | 0.051 ± 0.0207 | -0.034 ± 0.0221 |
| Month 18 | 0.078 ± 0.0300 | 0.027 ± 0.0323 |
| Month 24 | 0.117 ± 0.0429 | 0.060 ± 0.0466 |
| Month 30 | 0.094 ± 0.0494 | 0.129 ± 0.0534 |
| Month 36 | 0.119 ± 0.0597 | 0.197 ± 0.0644 |
Collected over Treatment-emergent adverse events (TEAEs) are events occurring from Month 12 of treatment (AURORA 2 baseline) up to 30 days after study treatment end in AURORA 2 (Month 37).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voclosporin | 0/116 (0%) | 21/116 (18.1%) | 84/116 (72.4%) |
| Placebo Oral Capsule | 3/100 (3%) | 23/100 (23%) | 60/100 (60%) |
| Event | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Corona virus infectionInfections and infestations | 2/116 | 5/100 |
| Lupus nephritisRenal and urinary disorders | 2/116 | 3/100 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 1/116 | 3/100 |
| Pneumonia viralInfections and infestations | 0/116 | 2/100 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/116 | 2/100 |
| Urinary tract infectionInfections and infestations | 2/116 | 0/100 |
| Disseminated tuberculosisInfections and infestations | 0/116 | 1/100 |
| GastroenteritisInfections and infestations | 1/116 | 1/100 |
| PneumoniaInfections and infestations | 1/116 | 1/100 |
| Radius fractureInjury, poisoning and procedural complications | 0/116 | 1/100 |
| Event | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Urinary tract infectionInfections and infestations | 14/116 | 8/100 |
| Glomerular filtration rate decreasedInvestigations | 11/116 | 5/100 |
| Upper respiratory tract infectionInfections and infestations | 10/116 | 3/100 |
| Viral upper respiratory tract infectionInfections and infestations | 10/116 | 4/100 |
| DiarrhoeaGastrointestinal disorders | 10/116 | 5/100 |
| HypertensionVascular disorders | 10/116 | 6/100 |
| Corona virus infectionInfections and infestations | 5/116 | 8/100 |
| Oedema peripheralGeneral disorders | 4/116 | 8/100 |
| Herpes zosterInfections and infestations | 4/116 | 7/100 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 5/116 | 7/100 |
Intent-to-Treat is comprised of all subjects who were randomized treatment during AURORA 1 AND who consented to continue their treatment in AURORA 2. Baseline values were collected at the start of AURORA 1 but only for subjects that continued in AURORA 2. Intent-to-Treat population was used for analysis of all Outcome Measures. Safety population comprised all randomized subjects who took at least one dose of study treatment, and was used for AE and SAE reporting.
| Age, Continuous(years) | Voclosporin | Placebo Oral Capsule | Total |
|---|---|---|---|
| Mean | 32.3 ± 10.31 | 35.4 ± 11.64 | 33.7 ± 11.03 |
| Sex: Female, Male(Participants) | Voclosporin | Placebo Oral Capsule | Total |
|---|---|---|---|
| Female | 105 | 88 | 193 |
| Male | 11 | 12 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Voclosporin | Placebo Oral Capsule | Total |
|---|---|---|---|
| Hispanic or Latino | 39 | 33 | 72 |
| Not Hispanic or Latino | 77 | 67 | 144 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Voclosporin | Placebo Oral Capsule | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 30 | 30 | 60 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 18 | 7 | 25 |
| White | 44 | 40 | 84 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 24 | 23 | 47 |
| Region of Enrollment(participants) | Voclosporin | Placebo Oral Capsule | Total |
|---|---|---|---|
| United States | 15 | 9 | 24 |
| Southeast Asia | 29 | 27 | 56 |
| Europe | 38 | 37 | 75 |
| South America | 34 | 27 | 61 |
| Lupus Nephritis (LN) history(years) | Voclosporin | Placebo Oral Capsule | Total |
|---|---|---|---|
| Years since diagnosis of systemic lupus erythematosus (SLE) | 6.6 ± 6.66 | 7.3 ± 6.85 | 6.9 ± 6.75 |
| Years since diagnosis of lupus nephritis (LN) | 4.8 ± 5.27 | 5.0 ± 5.23 | 4.9 ± 5.24 |
| Years since first instance of significant proteinuria (>500 mg/day) | 5.0 ± 5.15 | 4.7 ± 4.49 | 4.8 ± 4.85 |
| Baseline Urine Protein Creatinine Ratio (UPCR)(mg/mg) | Voclosporin | Placebo Oral Capsule | Total |
|---|---|---|---|
| Mean | 3.941 ± 2.5766 | 3.868 ± 2.4764 | 3.907 ± 2.5251 |
| Baseline estimated glomerular filtration rate (eGFR)(mL/min/1.73 m^2) | Voclosporin | Placebo Oral Capsule | Total |
|---|---|---|---|
| Mean | 94.1 ± 31.36 | 92.0 ± 28.04 | 93.2 ± 29.82 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Oct 2021, 24 months.
Results were first posted in Dec 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voclosporin
Aurinia Pharmaceuticals Inc.